Tau Consortium’s mission is to accelerate the development of new treatments for Alzheimer’s disease.
Tau Consortium is a collaborative research program that is managed and funded by the Rainwater Charitable Foundation in partnership with other funders.They commission world-class research and drug discovery to treat and prevent primary tauopathies like progressive supranuclear palsy, as well as secondary ones such as Alzheimer’s disease. They strategy is to engage and support talented researchers.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jan 17, 2019
Aquinnah Pharmaceuticals
|
Grant | $750K | Health Care | — |